CLINICAL_TRIALS
trial_result
· 2008-03-04
Clinical Trial Update: Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria [Phase 3]
Summary
This update notes the completion of a Phase 3 trial evaluating eculizumab (Soliris) for paroxysmal nocturnal hemoglobinuria.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Hemoglobinuria, Paroxysmal | Phase 3 | Status: COMPLETED